These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
532 related articles for article (PubMed ID: 17378764)
1. Cellular responses to viral infection in humans: lessons from Epstein-Barr virus. Hislop AD; Taylor GS; Sauce D; Rickinson AB Annu Rev Immunol; 2007; 25():587-617. PubMed ID: 17378764 [TBL] [Abstract][Full Text] [Related]
2. Interleukin 15-mediated induction of cytotoxic effector cells capable of eliminating Epstein-Barr virus-transformed/immortalized lymphocytes in culture. Sharif-Askari E; Fawaz LM; Tran P; Ahmad A; Menezes J J Natl Cancer Inst; 2001 Nov; 93(22):1724-32. PubMed ID: 11717333 [TBL] [Abstract][Full Text] [Related]
3. Cell-mediated immunity against Epstein-Barr virus infected B lymphocytes. Klein E; Masucci MG Springer Semin Immunopathol; 1982; 5(1):63-73. PubMed ID: 6314570 [No Abstract] [Full Text] [Related]
4. Primary immunodeficiencies and the control of Epstein-Barr virus infection. Palendira U; Rickinson AB Ann N Y Acad Sci; 2015 Nov; 1356():22-44. PubMed ID: 26415106 [TBL] [Abstract][Full Text] [Related]
9. Development of Epstein-Barr virus-specific memory T cell receptor clonotypes in acute infectious mononucleosis. Silins SL; Cross SM; Elliott SL; Pye SJ; Burrows SR; Burrows JM; Moss DJ; Argaet VP; Misko IS J Exp Med; 1996 Nov; 184(5):1815-24. PubMed ID: 8920869 [TBL] [Abstract][Full Text] [Related]
10. Cytotoxic effector cells from infectious mononucleosis patients in the acute phase do not specifically kill Epstein-Barr virus genome-carrying lymphoid cell lines. Patel PC; Dorval G; Menezes J Infect Immun; 1982 Oct; 38(1):251-9. PubMed ID: 6292093 [TBL] [Abstract][Full Text] [Related]
11. Role for early-differentiated natural killer cells in infectious mononucleosis. Azzi T; Lünemann A; Murer A; Ueda S; Béziat V; Malmberg KJ; Staubli G; Gysin C; Berger C; Münz C; Chijioke O; Nadal D Blood; 2014 Oct; 124(16):2533-43. PubMed ID: 25205117 [TBL] [Abstract][Full Text] [Related]
12. The effect of tinidazole on primary EBV infection and immunocompetence. Marklund G; Ernberg I; Britton S; Lundberg C Scand J Infect Dis; 1984; 16(1):17-23. PubMed ID: 6320359 [TBL] [Abstract][Full Text] [Related]
13. Role of human natural killer cells during Epstein-Barr virus infection. Münz C Crit Rev Immunol; 2014; 34(6):501-7. PubMed ID: 25597312 [TBL] [Abstract][Full Text] [Related]
14. Defective generation of killer cells against spontaneously Epstein-Barr virus (EBV)-transformed autologous B cells in a fatal EBV infection. Yanagisawa M; Kato M; Ikeno K; Kobayashi T; Miyagawa Y; Komiyama A; Akabane T Clin Exp Immunol; 1987 May; 68(2):251-8. PubMed ID: 2820633 [TBL] [Abstract][Full Text] [Related]
15. Immediate early and early lytic cycle proteins are frequent targets of the Epstein-Barr virus-induced cytotoxic T cell response. Steven NM; Annels NE; Kumar A; Leese AM; Kurilla MG; Rickinson AB J Exp Med; 1997 May; 185(9):1605-17. PubMed ID: 9151898 [TBL] [Abstract][Full Text] [Related]
16. Epitope focusing in the primary cytotoxic T cell response to Epstein-Barr virus and its relationship to T cell memory. Steven NM; Leese AM; Annels NE; Lee SP; Rickinson AB J Exp Med; 1996 Nov; 184(5):1801-13. PubMed ID: 8920868 [TBL] [Abstract][Full Text] [Related]
17. T-cell control of herpesvirus infections: lessons from the Epstein-Barr virus. Rickinson AB Prog Brain Res; 1983; 59():189-202. PubMed ID: 6320264 [No Abstract] [Full Text] [Related]
18. Long-term T-cell-mediated immunity to Epstein-Barr virus. Rickinson AB; Moss DJ; Wallace LE; Rowe M; Misko IS; Epstein MA; Pope JH Cancer Res; 1981 Nov; 41(11 Pt 1):4216-21. PubMed ID: 6272965 [No Abstract] [Full Text] [Related]
19. EBV-associated mononucleosis leads to long-term global deficit in T-cell responsiveness to IL-15. Sauce D; Larsen M; Curnow SJ; Leese AM; Moss PA; Hislop AD; Salmon M; Rickinson AB Blood; 2006 Jul; 108(1):11-8. PubMed ID: 16543467 [TBL] [Abstract][Full Text] [Related]
20. Brief report: killer cell defect and persistent immunological abnormalities in two patients with chronic active Epstein-Barr virus infection. Joncas J; Monczak Y; Ghibu F; Alfieri C; Bonin A; Ahronheim G; Rivard G J Med Virol; 1989 Jun; 28(2):110-7. PubMed ID: 2544675 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]